Synairgen plc’s Trend Down, Especially After Today’s Weak Session

 Synairgen plc's Trend Down, Especially After Today's Weak Session

The stock of Synairgen plc (LON:SNG) is a huge mover today! The stock decreased 2.58% or GBX 0.4 on November 23, hitting GBX 15.1. About 623,159 shares traded hands or 283.27% up from the average. Synairgen plc (LON:SNG) has declined 50.79% since April 22, 2016 and is downtrending. It has underperformed by 56.12% the S&P500.
The move comes after 8 months negative chart setup for the GBX 13.93M company. It was reported on Nov, 23 by Barchart.com. We have GBX 13.74 PT which if reached, will make LON:SNG worth GBX 1.25 million less.

Synairgen plc (LON:SNG) Ratings Coverage

Out of 2 analysts covering Synairgen PLC (LON:SNG), 2 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. GBX 137 is the highest target while GBX 46 is the lowest. The GBX 91.50 average target is 505.96% above today’s (GBX 15.1) stock price. Synairgen PLC has been the topic of 12 analyst reports since July 22, 2015 according to StockzIntelligence Inc. The rating was maintained by FinnCap with “Corporate” on Tuesday, August 30. The firm has “Corporate” rating given on Thursday, September 22 by FinnCap. The stock has “Buy” rating given by N+1 Singer on Wednesday, July 22. The rating was maintained by N+1 Singer with “Buy” on Wednesday, August 5. The firm has “Corporate” rating given on Wednesday, October 12 by FinnCap. FinnCap maintained Synairgen plc (LON:SNG) on Wednesday, August 5 with “Corporate” rating. N+1 Singer maintained the stock with “Buy” rating in Thursday, September 22 report. On Thursday, January 28 the stock rating was maintained by N+1 Singer with “Buy”. As per Tuesday, November 17, the company rating was maintained by FinnCap. N+1 Singer maintained the stock with “Buy” rating in Wednesday, September 16 report.

More news for Synairgen plc (LON:SNG) were recently published by: Fool.Co.Uk, which released: “Are Synairgen plc or Immupharma plc better investments than AstraZeneca plc?” on June 07, 2016. Reuters.com‘s article titled: “BRIEF-Synairgen says AstraZeneca decided to stop phase IIa AZD9412 trial” and published on October 12, 2016 is yet another important article.

Synairgen plc is a holding company. The Firm is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including severe asthma, chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis (IPF). The company has a market cap of 13.93 million GBP. The Firm uses its human biology BioBank platform to discover and develop therapies for respiratory disease. It currently has negative earnings. Using the BioBank platform, it has developed a number of tissue models, which include In vitro and Ex vivo models.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment